Pullar T, Capell H A
Drugs. 1986;32 Suppl 1:54-7. doi: 10.2165/00003495-198600321-00011.
Studies of sulphasalazine in rheumatoid arthritis have used largely empirical doses. The available literature suggests that the optimum dose appears to be greater than 40 mg/kg/day. Despite the relationship between dose and efficacy and a good correlation between dose and serum concentrations of sulphasalazine and its metabolites, no relationship has been demonstrated between efficacy and serum concentrations of sulphasalazine or its metabolites, although there is some suggestion that higher concentrations on single dosing are achieved in patients who develop upper gastrointestinal symptoms. Furthermore, acetylator phenotype does not affect efficacy, although upper gastrointestinal symptoms are more common in slow acetylators.
对类风湿性关节炎患者使用柳氮磺胺吡啶的研究大多采用经验性剂量。现有文献表明，最佳剂量似乎大于40毫克/千克/天。尽管剂量与疗效之间存在关联，且柳氮磺胺吡啶及其代谢产物的剂量与血清浓度之间具有良好的相关性，但尚未证明柳氮磺胺吡啶或其代谢产物的疗效与血清浓度之间存在关联，不过有迹象表明，出现上消化道症状的患者单次给药时浓度较高。此外，乙酰化表型不影响疗效，尽管上消化道症状在慢乙酰化者中更为常见。
